These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22410456)

  • 21. The current and emerging role of immunotherapy in prostate cancer.
    Madan RA; Gulley JL
    Clin Genitourin Cancer; 2010 Dec; 8(1):10-6. PubMed ID: 21208850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
    Paller CJ; Antonarakis ES
    Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C; Ferro M; Di Lorenzo G
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A New Era of Immunotherapy in Prostate Cancer.
    Pizzola C; Rizvi SM; Joshi M
    Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic vaccines for prostate cancer: recent advances and future directions.
    Strauss J; Madan RA
    Expert Rev Vaccines; 2016 Jul; 15(7):907-14. PubMed ID: 26889831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer immunotherapy: the path forward.
    Madan RA; Gulley JL
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):225-230. PubMed ID: 28644303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for prostate cancer: False promises or true hope?
    Rekoske BT; McNeel DG
    Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in immunotherapy for the treatment of prostate cancer.
    Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
    Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
    Madan RA; Antonarakis ES; Drake CG; Fong L; Yu EY; McNeel DG; Lin DW; Chang NN; Sheikh NA; Gulley JL
    J Natl Cancer Inst; 2020 Jun; 112(6):562-573. PubMed ID: 32145020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
    Thara E; Dorff TB; Pinski JK; Quinn DI
    Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunotherapy: an emerging strategies against prostate castration resistant cancer].
    Mansi L; Thiery-Vuillemin A; Kalbacher E; Nguyen T; Maurina T; Nallet J; Kim S; Borg C; Kleinclauss F; Pivot X; Adotevi O
    Bull Cancer; 2012 Jul; 99 Suppl 1():S57-65. PubMed ID: 22516539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer vaccines.
    Michael A; Relph K; Annels N; Pandha H
    Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances revolutionize treatment of metastatic prostate cancer.
    Madan RA; Arlen PM
    Future Oncol; 2013 Aug; 9(8):1133-44. PubMed ID: 23902245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.